Theme: Emerging trends with new innovations in proteomics and bioinformatics
Global Omics Conferences
Welcome to Proteomics-2015
5th International Conference on Proteomics and Bioinformatics is going to be held during September 01-03, 2015 at Valencia, Spain which includes central topics on Mass Spectrometry in Proteome Research, Molecular Modelling and Drug Design, Systems Biology, Functional genomics, and Recent Advancements in Proteomics and Bioinformatics. OMICS International Organizes 300+ conferences, 500+workshops and 200+symposiums on Clinical, Medicine, Pharma and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
Proteomics market analysis has its growth in case of Proteomics equipment’s and technologies this has made enormous progress in past few years, and according to the Market Research, value of proteomics market was $9.3 billion in 2012, and is expected to reach $21.63 billion by 2018, at a Compound Annual Growth Rate of 15.1%. Europe accounts for the second-largest share in the global proteomics market, in which Spain is one of the leading contributing states. Valencia is considered to be a hot spot for various researches which are carried out in the field of Proteomics.
For more details, please visit: Proteomics Analysis Data
Proteomics is an emerging field that has been highly enabled by the human genome project. Proteins are the products of genes, the machinery of the cells in our bodies. When genes are disrupted, the proteins are also affected. When pathogens infect us, causing disease, proteins play a key role in signaling the presence and ridding us of these invaders. Almost every process that occurs in our cells – from the metabolization of simple sugar to the division of cells – is dependent on proteins for smooth operation. In general, proteomics seeks to detect and quantify as many proteins as possible. To do this, we often employ a very high tech method called mass spectrometry. Protein analysis to yield more direct understanding of function and regulation of genes. The identification of autoantibodies to tumor cell proteins by proteomics approaches has great potential impact on cancer proteomics and biomarker discovery. Proteomics can detect immune-reactivity directed against protein post-translational modifications. Two-dimensional gel based Western blots, protein antigen microarrays, and multiplex ELISA reactions have been applied by our group to antigen based biomarker detection and validation. Microarray technology is usually used for gene expression profiling. It provides a practical method for measuring the expression level of thousands of genes simultaneously. Gene expression profiling of cancers proteomics represents the largest research category using microarrays and appears to be the most robust approach for molecular characterization of cancers such gene expression data allow us to identify genes which are expressed in a given cell type under a particular condition and time, to identify key players or target genes in signaling pathways, to recognize new targets of drugs, to find molecular markers in disease diagnosis. They are more than 4000 universities/institutions who do their research works in the various fields of Proteomics. The global proteomics market was valued at nearly $5.1 billion in 2014 and is growing at a compound annual growth rate (CAGR) of 18.0% to reach a forecast value of $11.6 billion by 2019. The global proteomics market, which covers: technologies, database and software markets, equipment markets, application markets and service markets. Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019. Some of the major players in the market include Thermo Fisher Scientific Corporation (U.S.), Agilent Technologies (U.S.), and Bio-Rad Laboratories (U.S.).
Proteomics is an emerging field that has been highly enabled by the human genome project. Proteins are the products of genes, the machinery of the cells in our bodies. Protein mass spectrometry refers to the application of proteomics mass spectrometry to the study of proteins. Peptide Mass spectrometry is an important emerging method for the characterization of proteins. Mass spectrometry (MS) measures the mass-to-charge ratio of ions to identify and quantify molecules in simple and complex mixtures.MS has become invaluable across a broad range of fields and applications, including proteomics. The development of high-throughput and quantitative MS proteomics workflows within the last two decades has expanded the scope of what we know about protein structure, function, modification and global protein dynamics.
This overview outlines the role of proteomics mass spectrometry in the field of proteomics and reviews MS methodology and instrumentation and touches on sample preparation and liquid chromatography-based separation prior to MS analysis. The rapid development of mass spectrometric technologies applied to protein research has catalysed entirely new experimental approaches and opened up new types of biological questions to experimentation, culminating in the field of proteomics. Two-dimensional gel electrophoresis can be used to create cellular protein maps which give a quantitative and qualitative picture of the proteome databases. Peptide Mass spectrometry is the method of choice for the rapid large-scale identification of these proteomes and their modifications. Proteogenomics uses mass spectrometry data to experimentally validate gene products and to assist in the process of genome annotation and comparison. The global mass spectrometry market is currently witnessing a healthy growth due to the increasing demand for hyphenated and tandem techniques that involve proteomics mass spectroscopy. The application areas include industries such as pharmaceuticals, biotechnology, research, environment testing, and food and beverage, among others. The major players in mass spectrometry market include Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Agilent Technologies (U.S.), Bruker Corporation (U.S.), Waters Corporation (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), and Shimadzu Corporation (Japan), among others. In the U.S., the National Institutes of Health funded the University of Georgia with a grant of $1.2 million for biomedical research. In Europe, Germany has increased its funding for research, and in the U.K.; mass spectrometry in proteomics is used in the food testing processes.
Proteomics is the large-scale study of proteins, particularly their structures and functions. Proteins are vital parts of living organisms, as they are the main components of the physiological metabolic pathways of cells. Biological databases are libraries of life sciences information, collected from scientific experiments, published literature, high-throughput experiment technology, and computational analysis. They contain information from research areas including genomics, proteomics, metabolomics, microarray gene expression, and phylogenetics. Genome sequencing of humans and other organisms has led to the accumulation of huge amounts of data, which include immunologically relevant data. The National Cancer Institute (NCI) Clinical Proteomics Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods. The global bioinformatics market accounted for $4.2 billion in 2014 and is poised to reach $13.3 billion by 2020 at a CAGR of 20.9% from 2015 to 2020. The bioinformatics platforms product segment is expected to witness the fastest growth during the forecast period. North America accounted for the largest market share of the bioinformatics market, followed by Europe, in 2014. However, Asian and Latin American countries represent emerging markets, owing to a rise in research outsourcing by pharmaceutical giants, increasing number of contract research organizations (CROs), rise in public and private sector investment, and growing industry -academia partnerships. The major players in the bioinformatics market are Affymetrix, Inc. (U.S.), Life Technologies Corporation (U.S.), Illumina, Inc. (U.S.), and QIAGEN(The Netherlands).
Molecular modelling encompasses all theoretical methods and computational techniques used to model or mimic the behaviour of molecules. Molecular modelling methods are now routinely used to investigate the structure, dynamics, surface properties and thermodynamics of inorganic, biological and polymeric systems. Molecular Modelling and Drug Design has evolved a great deal over the past 30 years. Modelling of proteins mass and bio molecular targets approximation to QSAR. Recent applications of density functional proteomics theory and molecular dynamics in relevant systems are reviewed. Damage to DNA induces several cellular responses and all DNA repair mechanisms. Focused on development of novel therapeutics also emerging chemistry in drug discovery and smart drug delivery, a method of delivering medication to a patient. The average cost of developing new drug molecules and the time taken to market them is pretty high. Today, almost every multi-national drug company and Contract Research Organization (CRO) involved in drug discovery has adopted computational methodology. There are numerous societies, organizations, institutions that are around 590+ who involved in the study of molecular modelling and drug design as they conduct many proteomics conferences, proteomics workshops as well as proteomics meetings. Around more than 1000+ people including researchers, doctorates, delegates, technicians from Universities, biological companies, laboratories, research and pharmaceutical companies were into the molecular modelling research. Around 20+ resources and research groups, journal group acts as funding groups to support this field. The bioinformatics sector is segmented into medical bioinformatics, animal bioinformatics, agriculture bioinformatics, academics and others. The Medical bioinformatics was and is forecast to be the highest revenue generating market through 2020. This was due to the increasing application of drug discovery and development using bioinformatics tools, which were also used in the preventive medicine and gene therapy. The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion for the period 2014-2019.
To understand complex biological molecular proteomics and systems requires the integration of experimental and computational research provides a powerful foundation from which to address critical scientific questions. Computational systems biology addresses questions fundamental to our understanding of life, yet progress here will lead to practical innovations in medicine, drug discovery and engineering. Insisting the value of high quality protein-protein interaction networks for systems biology. Networks contain a large amount of useful information for the functional proteomics characterization of protein mass. The recent revolution in high-throughput technologies offers an exciting opportunity to study such complex biological systems by new approach called systems biology. A large part of the incentive for using machine learning techniques in this area comes from the incompleteness of detailed knowledge. We intend to introduce some fundamentals of molecular proteomics systems biology and machine learning and present a current state of the art of the machine learning applied to molecular proteomics and systems biology. Genome sequencing technology has led to many recent scientific breakthroughs. The publication of the human genome sequence is the groundwork for further assessment of post-transcriptional and post-translational events occurring in a human cell. Human genome sequence information reveals that genome sequences from person to person are almost (99.9).The completion of the human genome sequencing projects is possibly one of the major advances in biology. This market search report focuses on the current and future applications of Systems Biology. The systems biology market is rapidly evolving, with various technological advancements that have resulted in a paradigm shift within the market the medical application segment accounted for a major share of the systems biology applications market in 2013. North America accounted for the largest share of the global systems biology market, followed by Europe, Asia, and the Rest of the World. In the coming years, Europe is expected to witness the highest growth rate. According to this systems biology market report, the industry is expected to reach $5,630.4 Million by 2018 from $1,923.1 Million in 2013, growing at a CAGR of 24% during the forecast period.
Machine learning is preferred approach to Medical outcomes analysis, Computational biology.Aim is to study the theory, implement them and application of computational techniques to problems in biology and medicine. Improves with experience through data, knowledge, experimentation and analysing data from High-throughput methods for gene expression. Providing a comprehensive introduction to the fields of Pattern Recognition and Machine Learning. Discussing about the machine learning tools and techniques how to use them. Proposing an ensemble technique in predicting protein mass secondary structure by Machine learning approach. Supervised learning models such as support vector machines with associated machine learning algorithms. Machine Learning Markets which provide mechanisms for building large scale machine learning models from component parts that trade information via purchases and sales in combinatorial information markets. Recently, prediction markets have shown considerable promise for developing flexible mechanisms for machine learning. We have been working to show that machine learning markets can capture many of the standard compositional structures in machine learning.
Genomics is the new science that deals with the discovery and noting of all the sequences in the entire genome of a particular organism. The genome can be defined as the complete set of genes inside a cell. Functional proteomics genomics is a field of molecular biology that attempts to make use of the vast wealth of data produced by genomic and transcriptomic projects (such as genome sequencing projects and RNA-seq) to describe gene (and protein) functions and interactions. McDonnell Genome Institute is applying next generation sequencing technology to analyse the genomes of these organisms and characterize the communities they form in healthy and diseased individuals. This research could ultimately provide doctors with new diagnostic and therapeutic approaches for a number of diseases. Metagenomics refers to the study of genomic DNA obtained from microorganisms that cannot be cultured in the laboratory. This represents the vast majority of terrestrial microorganisms. Microbial populations occur in every biological niche on earth. Recent advances in DNA sequencing have revolutionized the field of genomics, making it possible for even single research groups to generate large amounts of sequence data very rapidly and at a substantially lower cost. These high-throughput sequencing technologies make deep transcriptome sequencing and transcript quantification, whole genome sequencing and resequencing available to many more researchers and projects. The global market for genomics is expected to reach USD 22.1 billion by 2020, growing at an estimated CAGR of 10.3% from 2014 to 2020, according to a new study by Grand View Research, Inc. Global genomics market is forecasted to be worth 22.1 Billion by 2020.
Proteomics applications is the large-scale study of proteins, particularly their structure and functions, including detection, identification, measurement of their concentration, characterization of modification, characterization of protein-protein interaction and regulation. Proteomics applications research includes the characterization of protein mixtures in order to understand complex biological systems and determine relationships among proteins, their functions, and protein-protein interactions. Recently, genomic and proteomic technologies have evolved rapidly in cancer proteomics research. Genomic technologies allow us to monitor thousands of gene expression profiles simultaneously and evaluate interactions of candidate genes to obtain a global view of cancerous tissue in a single unbiased experiment. Mass spectrometry in proteomics is a sensitive technique used to detect, identify and quantitate molecules based on their mass and charge. Our desire to understand the proteome databases has led to new technologies that push the boundary of mass spectrometry capabilities, which in return has allowed mass spectrometry to address an ever-increasing array of biological questions. Recent successes illustrate the role of mass spectrometry-based proteomics as an indispensable tool for molecular and cellular biology and for the emerging field of systems biology. Neuroproteomics is the study of the protein analysis complexes and species that make up the nervous system. These proteins interact to make the neurons connect in such a way to create the intricacies that nervous system is known for. Neuroproteomics is a complex field that has a long way to go in terms of profiling the entire neuronal proteome. Meta-analysis comprises statistical methods for contrasting and combining results from different studies in the hope of identifying patterns among study results, sources of disagreement among those results, or other interesting relationships that may come to light in the context of multiple studies.
About the Gene therapy, an experimental technique that uses genes to treat or prevent disease. Embracing the latest advances in molecular medicines and targeted drugs designed to interfere with specific molecule. Monitoring of new antibiotic resistance elements that exploit the power of the genome revolution. Large-scale meta-analysis of genome-wide association data identifies new risks in this field. Supports Database building and management that includes connecting functional genomic data with pathways and networks, statistical aspects of the research and the need for researchers which employ tools to simplify the management of data. The field of clinical proteomics and bioinformatics includes development of personalized healthcare, medication and therapies development of bioinformatics methodologies for clinical proteomics research, and human databases. a new way to focus on the combination of clinical measurements and signs with human tissue-generated bioinformatics. Genome sequencing refers to the process of identifying the regions of genomic DNA that encode genes the process of subjecting a DNA, RNA or peptide mass spectrometry sequence to analytical methods to understand its features, function, structure, or evolution focused on deciphering the important information encoded in the human and other genomes. Molecular Phylogenetics and Evolution is dedicated to the studies that advance our understanding of phylogeny and evolution. Encourages new findings on or insights into evolutionary processes and mechanisms as expressed at the molecular level. Coming to programming languages Perl and Python both acts specially as bioinformatics resources. It’s a tool for Automated Analysis of Biological Sequence Data and manipulating the bioinformatics data it is a distributed collaborative effort to develop Python libraries and applications which address the needs of current and future work in bioinformatics. The bioinformatics market is expected to grow to $12.86 billion by 2020 with a CAGR of 21.2% during 2014-2020.The major factors driving the bioinformatics market is the need for integrated data, rising demand for drug development and discovery. The reason to study this market is to understand the current trends and applications in the bioinformatics field along with in depth analysis of the segments that follows. Bioinformatics Technology and Services, Application, Sector, Geographic, Competitive Landscape Market Analysis. In the past, the R&D activity in the biotechnology and pharmaceutical industry had a restrictive budget. However, due to the advancement in the IT solutions, the cost involved in the R&D activity has become cost and time efficient.